[ad_1]
Dr. Reddy’s Laboratories on Friday (September 6, 2024) said it has received the Establishment Inspection Report (EIR) from the US health regulator for its active pharmaceutical ingredient manufacturing facility (CTO-6) at Srikakulam in Andhra Pradesh.
The Hyderabad-based drugmaker said in a statement that the US Food and Drug Administration (USFDA) has classified the inspection as a Voluntary Action Indicated (VAI) and concluded that the inspection is close.
According to the USFDA, a VAI means that objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
On June 7 this year, Dr Reddy’s had said the US healthcare regulator had issued Form 483 with four observations after inspecting its Srikakulam facility.
On Friday, the company’s shares closed at Rs 6,669.75, down 0.42% on BSE.
Published – September 06, 2024 11:03 pm IST
[ad_2]
Source link